EP4161506A4 - Isotopically labeled psychodelic triptamines for use in pharmacology or clinical treatments - Google Patents

Isotopically labeled psychodelic triptamines for use in pharmacology or clinical treatments

Info

Publication number
EP4161506A4
EP4161506A4 EP21801398.5A EP21801398A EP4161506A4 EP 4161506 A4 EP4161506 A4 EP 4161506A4 EP 21801398 A EP21801398 A EP 21801398A EP 4161506 A4 EP4161506 A4 EP 4161506A4
Authority
EP
European Patent Office
Prior art keywords
triptamines
psychodelic
pharmacology
isotopically labeled
clinical treatments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21801398.5A
Other languages
German (de)
French (fr)
Other versions
EP4161506A1 (en
Inventor
Rivas Lucía Fernando Minini
Chiesa Fernando Amaury Ferreira
Araújo Dráulio Barros De
Dellavalle Paola Alexadra Diaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomind Labs Inc
Original Assignee
Biomind Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomind Labs Inc filed Critical Biomind Labs Inc
Publication of EP4161506A1 publication Critical patent/EP4161506A1/en
Publication of EP4161506A4 publication Critical patent/EP4161506A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP21801398.5A 2021-08-17 2021-09-22 Isotopically labeled psychodelic triptamines for use in pharmacology or clinical treatments Pending EP4161506A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163234038P 2021-08-17 2021-08-17
PCT/CA2021/051316 WO2023019344A1 (en) 2021-08-17 2021-09-22 Isotopically labeled psychodelic triptamines for use in pharmacology or clinical treatments

Publications (2)

Publication Number Publication Date
EP4161506A1 EP4161506A1 (en) 2023-04-12
EP4161506A4 true EP4161506A4 (en) 2024-01-24

Family

ID=85239297

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21801398.5A Pending EP4161506A4 (en) 2021-08-17 2021-09-22 Isotopically labeled psychodelic triptamines for use in pharmacology or clinical treatments

Country Status (2)

Country Link
EP (1) EP4161506A4 (en)
WO (1) WO2023019344A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760394A (en) 1996-05-17 1998-06-02 Welle; Richard P. Isotopic taggant method and composition
US7112445B1 (en) 2000-05-19 2006-09-26 Richard P Welle Fragmented taggant coding system and method with application to ammunition tagging
FR2874092B1 (en) 2004-08-05 2007-06-08 Innovation Et Chimie Fine Sarl PROCESS FOR THE ISOTOPIC MARKING OF PRODUCTS AND ITS APPLICATIONS IN PARTICULAR TO THE FIGHT AGAINST COUNTERFEIT
ES2320085B2 (en) 2009-02-13 2010-03-09 Universidad De Oviedo METHOD FOR THE MARKING AND IDENTIFICATION OF MANUFACTURED OBJECTS, SUBSTANCES AND ORGANISMS, AND THEIR USES.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JOSE A. SINTAS ET AL: "Synthesis of 131I derivatives of indolealkylamines for brain mapping", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 39, no. 8, 1 August 1997 (1997-08-01), GB, pages 677 - 684, XP055227452, ISSN: 0362-4803, DOI: 10.1002/(SICI)1099-1344(199708)39:8<677::AID-JLCR9>3.0.CO;2-G *
MARION DANIEL-BERTRAND ET AL: "Multiple Site Hydrogen Isotope Labelling of Pharmaceuticals", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE, HOBOKEN, USA, vol. 59, no. 47, 15 September 2020 (2020-09-15), pages 21114 - 21120, XP072102373, ISSN: 1433-7851, DOI: 10.1002/ANIE.202008519 *
POON GRACE ET AL: "Synthesis of psilocin labelled with 14 C and 3 H", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 23, no. 2, 1 February 1986 (1986-02-01), GB, pages 167 - 174, XP093111503, ISSN: 0362-4803, DOI: 10.1002/jlcr.2580230207 *
See also references of WO2023019344A1 *
SIMON D. BRANDT ET AL: "Microwave-accelerated synthesis of psychoactive deuterated N , N -dialkylated-[ [alpha] , [alpha] , [beta] , [beta] -d 4 ]-tryptamines", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 51, no. 14, 1 November 2008 (2008-11-01), GB, pages 423 - 429, XP055724013, ISSN: 0362-4803, DOI: 10.1002/jlcr.1557 *

Also Published As

Publication number Publication date
WO2023019344A1 (en) 2023-02-23
EP4161506A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
EP3250609A4 (en) Il13ra alpha 2 binding agents and use thereof in cancer treatment
EP2007385A4 (en) Cardiovascular composition and use the same for the treatment of alzheimers disease
NO20081842L (en) Methods and compositions for use in the treatment of patients with autoantibody-positive diseases
HK1135917A1 (en) Antibody against pdgfr-alpha for use in the treatment of tumours
BR112012008854A2 (en) combination, combination kit, use of a combination, pharmaceutical composition, and method for treating cancer in a human
DK2217577T3 (en) HIS UNKNOWN RELATIONSHIPS AND PREPARATIONS AND PROCEDURES FOR USE THEREOF
PL2254870T3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
BRPI0716985A2 (en) NUTRITIONAL COMPOSITION, USE OF THE SAME, AND NUTRITIONAL SUPPLEMENT FOR THE TREATMENT OF PATIENTS SUFFERING FROM FOOD ALLERGIES
DK2328417T3 (en) RELATIONSHIPS, PREPARATIONS AND METHODS FOR TREATING BETA AMYLOID DISEASES AND SYNUCLEINOPATHIES
IL207278A0 (en) 1 - benzyl - 3 - hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp - 1, and cx3cr1
IL202307A0 (en) Multikinase inhibitors for use in the treatment of cancer
DE112005002108A5 (en) Patient table for a radiotherapy or radiation diagnostic system
IL280921A (en) Cyclobenzaprine or amitriptyline containing compositions for use in treating stress disorders
IL185051A0 (en) Color-coded stainless steel fittings and ferrules
IL285062A (en) In vitro human blood brain barrier
BRPI0821100A2 (en) Compositions and Methods for the Treatment of Bladder Cancer
EP4161506A4 (en) Isotopically labeled psychodelic triptamines for use in pharmacology or clinical treatments
WO2009103010A3 (en) Alpha-synuclein kinase
IL275132A (en) C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
EP3781262A4 (en) Compositions and methods for treating cardiovascular disease in selected patients
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
BR112018076935A2 (en) composition, drug and method for the treatment of chemotherapy-induced alopecia
IL272078A (en) Cannabinoids for use in treatment
EP4104861A4 (en) Therapeutic agent for tauopathies
SG11202102437PA (en) Use of low volume plasma exchange for the treatment of alzheimer’s disease in early and middle stages

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

A4 Supplementary search report drawn up and despatched

Effective date: 20240102

RIC1 Information provided on ipc code assigned before grant

Ipc: C07F 9/572 20060101ALI20231219BHEP

Ipc: C07D 209/16 20060101ALI20231219BHEP

Ipc: C07D 209/08 20060101ALI20231219BHEP

Ipc: A61P 25/00 20060101ALI20231219BHEP

Ipc: A61K 31/675 20060101ALI20231219BHEP

Ipc: A61K 31/404 20060101ALI20231219BHEP

Ipc: A61K 31/4045 20060101AFI20231219BHEP

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA